Bristol Myers Squibb Beats on Q1 Sales, Profit; Stock Jumps 5% as Growth Portfolio Shines

Dividend increased for 17 straight years; shares offer 4.2% yield and a beta of just 0.2

Bristol Myers Squibb (BMY) gave investors a reason to stay calm on Thursday. The drugmaker posted first-quarter results that topped Wall Street forecasts, sending shares up more than 5% — and reminding the market why the stock is a favorite among income-focused, low-volatility portfolios.

Two beats, one clear driver

Revenue for the three months ended March 31 rose 3% year over year to $11.5 billion, easily exceeding the $10.9 billion consensus estimate. Non-GAAP earnings per share came in at $1.58, also above the expected $1.42.

The outperformance was fueled almost entirely by the company’s Growth Portfolio — newer drugs and recent launches — which generated $6.2 billion in sales. In contrast, the legacy portfolio of older medicines fell 6% to just under $5.3 billion.

Within the growth bucket, every drug except cancer immunotherapy Opdivo posted higher sales. On the legacy side, only blockbuster blood thinner Eliquis avoided a decline.

On a GAAP basis, net income dipped to $3.2 billion (1.58 per share) from $3.7 billion a year ago. But the drop is largely due to accounting items such as amortization of acquired assets. Adjusting for those, BMS’s bottom line landed 11% ahead of expectations — a beat that analysts say reflects the company’s underlying commercial strength.

Management reaffirmed full-year 2026 guidance: revenue of $46 billion to $47.5 billion, and adjusted EPS of $6.05 to $6.35. The average analyst forecast sits at $47.1 billion and $6.25, respectively — right in the middle of the company’s range. For long-term holders, such predictability is a feature, not a bug.

The real reasons to own BMS

The earnings beat was the spark for Thursday’s rally, but the stock’s long-term appeal rests on two numbers:

Beta of 0.2 – For every 1% move in the S&P 500, BMS shares move just 0.2% on average. In a volatile market, that’s essentially an anchor.

4.2% dividend yield – The company has raised its payout for 17 consecutive years, including through recessions and the pandemic. The current yield is well above the 10-year Treasury’s roughly 3.8%.

Not the trader chasing 100% gains. BMS doesn’t produce fireworks. But for investors looking to lower portfolio volatility, generate rising passive income, and sleep through the next Fed meeting, it fits the bill. The quarterly beat is just noise; the real story is 17 years of hikes, a 4.2% yield, and a 0.2 beta.